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Computational and Integrative Biology, Rutgers University-Camden, Camden, New JerseyABSTRACT Modulation of the GABA type A receptor (GABAAR) function by cholesterol and other steroids is documented at
the functional level, yet its structural basis is largely unknown. Current data on structurally related modulators suggest that
cholesterol binds to subunit interfaces between transmembrane domains of the GABAAR. We construct homology models of
a human GABAAR based on the structure of the glutamate-gated chloride channel GluCl ofCaenorhabditis elegans. The models
show the possibility of previously unreported disulfide bridges linking the M1 and M3 transmembrane helices in the a and g sub-
units. We discuss the biological relevance of such disulfide bridges. Using our models, we investigate cholesterol binding to in-
tersubunit cavities of the GABAAR transmembrane domain. We find that very similar binding modes are predicted independently
by three approaches: analogy with ivermectin in the GluCl crystal structure, automated docking by AutoDock, and spontaneous
rebinding events in unbiased molecular dynamics simulations. Taken together, the models and atomistic simulations suggest a
somewhat flexible binding mode, with several possible orientations. Finally, we explore the possibility that cholesterol promotes
pore opening through a wedge mechanism.INTRODUCTIONRapid inhibition in the vertebrate central nervous system is
mediated largely by the neurotransmitter g-aminobutyric
acid (GABA) acting on the GABA type A (GABAAR), a Cl

channel in the Cys-loop superfamily of ionotropic receptors
(1–3). Dysfunctional GABAARs have been implicated in mul-
tiple human diseases, including epilepsy (4), schizophrenia
(5–7), Alzheimer’s disease (8), and alcohol dependence
(9,10). Drugs treating these disorders, as well as multiple clas-
ses of anesthetics (11–13) and sedatives (14,15) target the
GABAAR. In addition, GABAARs are also modulated by
endogenous cholesterol derivatives called neurosteroids (16–
18), which function as natural sedatives, anesthetics, pain-
killers, anticonvulsants, and antianxiety agents (19).
The mechanisms through which both endogenous and
exogenous lipophilic modulators exert their effects on the
GABAAR have not been conclusively determined. Eluci-
dating these mechanisms has proven challenging, in part
due to lack of information regarding the structure and dy-
namics of the GABAAR in the absence of these modulators.
No high-resolution crystal structures of the GABAAR have
been published; however, a general understanding of Cys-
loop receptor structure has emerged over the past decade
thanks to the publication of cryoelectron microscopy (cryo-
EM) images at medium resolution (20,21) obtained for
a cationic homolog (the nicotinic acetylcholine receptor
(nAChR)) and, more recently, high-resolution crystal struc-
tures of prokaryotic cationic members of the family,Dickeya
dadantii and Gloeobacter violaceus ligand-gated ion chan-
nels (ELIC (22,23) and GLIC (24–28), respectively).Submitted December 6, 2013, and accepted for publication March 14, 2014.
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0006-3495/14/05/1938/12 $2.00From these and earlier studies, it is known that ion
channels in this family are pentamers, with five subunits ar-
ranged around a central pore; consequently, they are often
called pentameric ligand-gated ion channels (pLGICs)
(29). It has also been shown that each subunit has an extra-
cellular domain composed of b sandwiches and a transmem-
brane domain composed of a four-helix bundle, with helices
labeled M1–M4. Some pLGICs also have a long intracel-
lular domain of unknown structure; in nAChRs, this domain
has been shown (30) to be unnecessary for function. Neuro-
transmitters bind to sites at subunit interfaces in the extra-
cellular domain, and the signal is transmitted to the pore
through a poorly understood mechanism (31).
Only one high-resolution structure for either a eukary-
otic or anion-selective member of the family has been pub-
lished (32): the glutamate-gated chloride channel (GluCl)
from Caenorhabditis elegans has been crystallized in the
open state in the presence of a lipophilic agonist (iver-
mectin) bound to the subunit interface in the transmem-
brane domain, and in both the presence and absence of
its neurotransmitter, glutamate. The conformation of the
structure in the absence of ivermectin is unknown. Based
on the orientation of ivermectin in those crystal structures,
Hibbs and Gouaux proposed that hydrogen bonding to M2
serine 150 is essential for potentiation and activation and
suggested that activation by ivermectin proceeded due to
a wedge mechanism in which the agonist increases the
radius of the ring formed by the M1 and M3 helices,
thus causing the inner ring, composed of pore-lining M2
helices, to expand. It was then proposed that hydrogen
bonding with Ser150 on M2 stabilizes the open state of
the receptor. However, such hydrogen bonds are not always
conserved in other Cys-loop receptors that are highly sen-
sitive to ivermectin, leading Lynagh and Lynch (33) tohttp://dx.doi.org/10.1016/j.bpj.2014.03.024
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of the mechanism.
Since ivermectin potentiates both GluCl and the
GABAAR in a similar manner, the modes of interaction
can be expected to be similar as well. On a structural level,
the ivermectin site in GluCl forms a cavity that transfers to
GluCl-based models of GABAARs. All available crystal
structures of GluCl have the agonist ivermectin bound to in-
tersubunit sites in the transmembrane domain, but relaxation
in the absence of bound ivermectin has been explored in two
recent computational studies (34,35). In these studies, the
empty site did not fill with water but saw a reduction in vol-
ume due to local changes in protein structure, whereas the
remaining cavity was filled with phospholipid chains from
the bilayer. We note that binding to the vacant site of other
lipophilic molecules, such as cholesterol, was excluded
from potential observation because both model bilayers
were made of pure phospholipid.
Still, numerous studies have indicated the existence of
specific interactions between eukaryotic pLGICs and choles-
terol, which is abundant in synapticmembranes (36). Interac-
tions of the nAChR with cholesterol have been extensively
studied (37–47) due to an early observation of a functional
requirement after purification and reconstitution; in such
systems, addition of cholesterol to a reconstitution mixture
can confer up to a fivefold gain of function. However, a
significant obstacle to quantifying effects of cholesterol
experimentally lies in the difficulties in controlling the
amount and distribution of cholesterol in the membrane-pro-
tein system.
Some later experiments, however, depleted the native
membranes of cholesterol using liposomes (42,48,49) or cy-
clodextrins (50–52); as indicated by the result that some
cholesterol (~36 molecules/receptor) remains in the system
despite extensive depletion (42), this procedure likely pri-
marily modulates the cholesterol content of the bulk mem-
brane. In a recent study, it was reported that the nAChR
reconstituted in bilayers free of cholesterol but of sufficient
thickness undergoes conformational transitions on a slow
timescale (minutes to hours) (53). Although those experi-
ments indicate a role for hydrophobic thickness in nAChR
modulation, they do not conclude that the nAChR can be
fully functional in the absence of cholesterol.
Simulation studies (54,55) have investigated interactions
between membrane cholesterol and the nAChR, although
timescales were likely insufficient to achieve mixing equi-
librium. After the publication of an atomic cryo-EM struc-
ture for the nAChR (20,21) exhibiting significant gaps in
transmembrane protein density, we proposed (54) that
cholesterol could occupy deeply buried (nonannular) sites,
and we demonstrated that models containing significant
amounts of embedded cholesterol were the most stable un-
der molecular dynamics (MD) simulation.
Interactions of the GABAAwith cholesterol have received
less attention, although purification and reconstitution pro-tocols for GABAARs either include cholesterol (56,57) or
yield nonfunctional and unstable receptors (56). Sooksawate
and Simmonds reported that coexisting indirect and direct
mechanisms account for cholesterol modulation of the
GABAAR (58); in this system, both enrichment and deple-
tion of cholesterol reduce the potency of the receptor, but
although the enrichment effect can be reproduced using
epicholesterol, the depletion effect cannot be reversed by
introducing epicholesterol. The authors hypothesize that
the depletion effect reflects direct interactions, whereas
the enrichment effect is mediated by physical properties
of the membrane. Consequently, due in part to the chal-
lenges inherent in controlling the amount or distribution
of cholesterol even in the experimental control systems, a
simple functional effect of directly bound cholesterol on
GABAARs has not been identified.
The presence of specific interactions of cholesterol with
GABAARs is further suggested by the observation that
such receptors can be positively modulated, and even acti-
vated, by cholesterol derivatives known as neurosteroids
(16–18). Two examples of potent, naturally occurring
GABAA-active steroids are 3a-hydroxy-5a-pregnan-20-
one (allopregnanolone) and 5a-pregnane-3a,21-diol-20-
one (THDOC). Positive Modulation by neurosteroids
requires a hydroxyl at C3, as in cholesterol, but also requires
a hydrogen-bond-accepting group at C20 (usually a ketone)
(19,59,60). The interface between a and b subunits in the
transmembrane domain of the GABAAR, in the same region
as the ivermectin site in GluCl, has been identified through
mutagenesis as the likely site of activation by the positively
modulating neurosteroids allopregnanolone and THDOC
(61,62), although this interpretation may depend on the
structural model considered (63). The mechanism through
which the different functional group at C20 allows the neu-
rosteroid to activate the receptors (in contrast to cholesterol,
which does not cause activation) has not been determined.
Modulation by neurosteroids is, however, dependent on
cholesterol concentration (64). Furthermore, the antago-
nistic effect upon cholesterol enrichment is selective of
cholesterol versus epicholesterol (58) and may therefore
be ascribed to specific cholesterol binding, possibly compet-
itive binding to the intersubunit sites.
Finally, some degree of pharmacological similarity be-
tween ivermectin and steroids at the GABAA transmem-
brane domain is expected. Ivermectin is known to bind to
GABAARs and potentiate their response to GABA or even
activate the receptors in the absence of GABA (65–67). A
binding site for cholesterol at the subunit interface also
forming the neurosteroid site would consequently be consis-
tent with the available data.
In this report, we explore potential specific interactions
between cholesterol and the intersubunit (ivermectin) sites
on several different models of an a1b1g2 GABAA receptor.
We find that docking calculations do place cholesterol in the
intersubunit sites. Using MD simulation, we explore theBiophysical Journal 106(9) 1938–1949
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as its short-time effects on transmembrane domain confor-
mation. In particular, we test whether such cholesterol acts
as a nonspecific wedge on the ring of M1 and M3 helices.METHODS
Homology modeling
No high-resolution structure of a GABAAR is presently available, but mul-
tiple structures for members of the pLGIC superfamily have been pub-
lished; for simulations of the GABAAR, we must rely on homology
models built on these templates. Such modeling is supported by two prop-
erties of pLGICs:
1. Alignments for the pLGIC superfamily are robust: large multiple align-
ments have been constructed using sophisticated methods for detecting
remote homology (68,69) and confirmed by structural alignment in the
cases where structures are available (ELIC, GLIC, and GluCl). Further-
more, accuracy of the calculations for this manuscript depend largely on
the resolution of the structure in the transmembrane domain, for which
the alignment between GABAAR and the template, GluCl, is essentially
unambiguous and has no gaps.
2. All existing structures indicate a tightly conserved fold for the pLGIC
superfamily, particularly in the transmembrane domain. Despite the
evolutionary distance (24% overall sequence identity) between GluCl
and GLIC, the protein backbones show remarkable overlap. In our
case, the model and template are likely even more similar: GluCl and
GABAAR (both anionic, eukaryotic, and ligand-gated) exhibit 32%
sequence identity overall, and 46% identity in the transmembrane domain.
Other groups have found available templates and alignments to yield
models of GABAARs robust enough for pharmacological studies (70,71).
We built homology models using GluCl (PDB code 3RHW) as a template
and the alignments published with that structure. The standard procedure
for oligomer modeling in MODELLER (72) was used to build 40 human
a1b1g2 GABAAR homology models from the template and alignments,
with disulfide bridges specified in the a and g transmembrane domains.
Stereochemistry was checked using the Chirality plugin (73) in VMD
(74), and the model with the lowest score was chosen for further simulation
(Model 1). To conservatively estimate the uncertainty in results due to
the use of a homology model with underdetermined side chains, a second
intermediate-scoring model (Model 2) that displayed an alternate pattern
of salt bridging in the transmembrane domain, including fivefold symmetry
for the salt bridges in the extracellular half of the transmembrane domain
(aM2:Arg274-M3:Asp287, bM2:Asp282-M3:Lys279, gM2:Arg284-M3:
Asp297), was also selected for simulation. To test for the influence
of modeling details on cholesterol-protein interactions, another alternate
model (Model 3) was constructed by further optimizing side chains using
the program SCWRL4 (75); orientation of polar side chains was then cor-
rected to optimize the hydrogen-bond network using MolProbity (76).Cholesterol docking
A first set of starting coordinates for bound cholesterol was generated by
analogy with ivermectin. The cyclohexanol ring of cholesterol was aligned
with the benzofuran moiety of ivermectin bound to the template, as shown
in Fig. S3; these poses retained the symmetry of the GluCl template, and
were not affected by pseudosymmetry of the GABAAR. These coordinates
were the initial conditions for simulations of Model 1 and Model 2.
Docking of cholesterol molecules to Model 3 was performed in a
completely independent manner: automated docking was performed by the
AutoDock Vina software package (77). Input files were prepared using the
University of California, San Francisco’s Chimera (78). All docking
attempts on search spaces including the hydrophobic pore returned bindingBiophysical Journal 106(9) 1938–1949poses in the pore, which are physiologically unrealistic. For that reason, the
pore itself was excluded from all production runs. In a first docking calcula-
tion, the cholesterol was flexible, whereas the protein was rigid, and the
search space included the complete transmembrane domain. A second stage
sought to refine the search in theb1-a1 andb1-g2 interfaces; in these searches,
two protein residues whose side chains were protruding into the intersubunit
spaceweremade flexible (b1,M227 andL231). Together, these searches pro-
duced a generally similar set of poses for cholesterol in all five intersubunit
clefts. To account for the absence of a lipid bilayer in docking calculations,
poses involving significant interactionswithmembrane-facing residueswere
excluded, assuming that cholesterol in such poses could be displaced by
phospholipids; deeply bound poses were favored. In a similar way, reverse
poses where the cholesterol hydroxyl was located outside the pocket were
excluded. After applying these criteria, there remained at least one high-
scoring pose for each site (within two score units of the maximum): the
best-scoring pose for each interface was selected for further modeling.Solvated simulation systems
The proteins with bound cholesterol and without cholesterol were both
placed in a lipid bilayer composed of 4:1 phosphatidylcholine (POPC)/
cholesterol mixture, generated using the CHARMM-GUI Membrane
builder (79) to build a patch of 72 POPC molecules and 18 cholesterol mol-
ecules, and then duplicating the patch three times in Visual Molecular
Dynamics (VMD). The cholesterol concentration of 20% is in the lower
part of the physiological range (36). This ensures a realistic bilayer struc-
ture, without running the risk of biasing cholesterol-protein interactions
toward excessive binding through a high cholesterol concentration. The
transmembrane domain of the protein (and any bound cholesterol) was
aligned to the membrane and overlapping lipids were removed. The final
system with bound cholesterol had 266 POPC molecules and 71 membrane
cholesterol molecules, whereas the final system with no bound cholesterol
had 268 POPC molecules and 71 membrane cholesterol molecules. The
system was solvated using the solvate plugin of VMD, and ions were added
to bring the system to a neutral 0.15 M concentration using the autoionize
plugin. The total system size was ~157,000 atoms for all systems.Simulation details
All simulations used the CHARMM22-CMAP force field with torsional
corrections for proteins (80,81). The CHARMM36 (82) model was used
for phospholipids, ions, and water. CHARMM36 (83) parameters were
used for cholesterol in Models 1 and 2, and updated, yet very similar param-
eters (CHARMM36c (84)) were used for Model 3. Energy minimization
and MD simulations were performed using the NAMD package versions
2.8 and 2.9 (85). All simulations employed periodic boundary conditions;
long-range electrostatics were handled with the smooth particle mesh
Ewald method (86), and a cutoff of 1.2 nm was used for Lennard-Jones po-
tentials, with a switching function applied starting at 1.0 nm. All simula-
tions were run in the NPT ensemble with weak coupling to a Langevin
thermostat and barostat at a respective 300 K and 1 atm. All bonds to
hydrogen atoms were constrained using the SHAKE/RATTLE algorithm.
A multiple-time-step rRESPA method was used, controlled with a high-fre-
quency time step of 2 fs and a low-frequency time step of 4 fs.
The systems were energy-minimized for 1000 steps, then simulated for
5 ns with restraints of 1 kcal/mol/A˚2 applied to the Ca atoms of the protein.
Restraints were then lifted, and 195 ns of nearly unrestrained simulation
was carried out. During this period of the simulation, only harmonic re-
straints (force constant, 0.4 kcal/mol/A˚2) between the intracellular ends
of the M3 andM4 helices were used, to mimic the effects of the intracellular
domain and prevent separation of the M4 helix from the rest of the bundle.
To provide an estimate for statistical error due to finite temperature, three
simulations (a–c) of Model 1-Chol were run; these replicas differ only in the
random seed used for the thermostat and barostat.
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Cholesterol orientation within the intersubunit cleft was measured along
two coordinates, a tilt angle and a flip angle. Tilt is defined as the angle be-
tween the long axis of cholesterol and the membrane plane. Here, the long
axis was defined as the vector joining atoms C3 and C17, at opposite ends of
the steroid nucleus. The flip angle is defined as the angle between the vector
joining cholesterol atoms C2 and C4 (in the b position of the hydroxyl
group) and the membrane plane.
Hydrogen bonds were defined as those with an O-H separation of<3.3 A˚
and an angle of <25. For analysis of pore profiles, snapshots were ex-
tracted every 1 ns from the simulations and were subsequently aligned.
The HOLE software (87) was used to measure pore radius for each snap-
shot, and the resulting pore profiles were analyzed and plotted using a
custom Python script. Measurements of geometric pore properties were
conducted using VMD scripts (for definitions, see Fig. 5).RESULTS
GABAA models
Three homology models of the a1b1g2 GABAA receptor
were built based on the recent crystal structure of the gluta-
mate-gated chloride channel (GluCl) from C. elegans (32)
(PDB code 3RHW). Several potentially essential interac-
tions in the transmembrane domain emerged in these
models. The most striking result was the existence of a po-
tential disulfide bridge in the core of the transmembrane
domain, in the a and g subunits, between helices M1 and
M3 (Fig. S1).
The template GluCl possesses two neighboring cysteine
residues, Cys225 on M1 and Cys283 on M3. Although
Cys283 faces M1, Cys225 points away from M3, so that
the side chains are too distant to form a disulfide bond in
GluCl (distance between Cb atoms, 7.9 A˚). GABAAR sub-
units a and g have a cysteine residue at the previous position
in the sequence, which points directly toward M3; this
brings the side chains within bonding distance in the confor-
mation directly derived from the template. As a test, we pro-
duced alternate models wherein this disulfide bond was or
was not enforced; this produced no significant changes to
the modeling score. Most likely, such disulfide bridges
were never envisioned because the previously available tem-
plate structure (Unwin’s structure of the nAChR) incorrectly
assigns residues in the transmembrane domain (88),
yielding homology models where the cysteines are not in
contact. Such a possibility is noted only in passing in one
recent report (71).
The alignment of this region is robust: for the region span-
ning M1–M3, there are no gaps in the multiple alignment,
and the three GABAA chains have sequence identities with
GluCl of 46%, 48%, and 41%, respectively. Thus, amisplace-
ment of the cysteine residues involved due to alignment er-
rors is very unlikely. This is confirmed by comparison with
the model of an a1b1g2 GABAAR published by Bergmann
et al. (70), which places the cysteine residues at the same po-
sitions, although the authors do not comment on the possibil-
ity of disulfide bridging. Based on the alignment of variousprokaryotic and eukaryotic pLGIC sequences by Tasneem
et al. (68), we examined the distribution of both cysteine res-
idues across receptor types and taxonomic groups. Interest-
ingly, although each of the cysteines is common among
eukaryotic pLGICs, this potentially bridging pair of cyste-
ines is rare (Fig. S2). The general trend is for prokaryotic re-
ceptors to lack both cysteines, for anionic as well as 5HT3
receptors to have only theM3 cysteine, and for acetylcholine
receptors to possess only theM1 cysteine, with only GABAA
a and g subunits having both. The only exceptions to these
rules are a few prokaryotic and invertebrate receptors. To
look for a possible functional significance of these residues,
we investigated their variability more specifically among
GABA receptor subunits through sequence alignments of
vertebrate GABAA subunits from the Uniprot database.
The pattern is conserved across subtypes and species: all an-
notated subunits of types a and g possess both cysteines,
whereas b subunits have the cysteine on M3 but lack that
on M1. This extends to vertebrates (most of the available
sequences), but also to invertebrates such as Lymnea and
Drosophila. The only exception we found is a GABA recep-
tor subunit b from C. elegans (Uniprot ID O18276), which
has both cysteines.
This raises the distinct possibility that the presence or
absence of these disulfide bridges is not neutral, but could
play a specific functional role in a and g subunits of
GABAARs at least in all vertebrate species. An argument
against such a role is the fact that wild-type receptors
seem functionally unaffected by exposure to the reducing
agent dithiothreitol (89,90). A more in-depth investigation
could involve mutagenesis, either mutating one of the
bridging cysteines to serine or introducing the missing M1
cysteine in a b subunit. Some of these experiments have
already been performed by Akabas and co-workers. Those
authors mutated endogenous cysteines from the a subunit
to prepare a Cys-light version of the receptor, as a back-
ground for cross-linking experiments (91,92). Unfortu-
nately, those studies do not report a functional comparison
of the Cys-light mutant with the wild-type.
Although the bridge is highly plausible from a geometric
perspective, it is unknown whether this region of the trans-
membrane domain is exposed to sufficient oxidizing condi-
tions after translation to effectively produce the disulfide.
Limited water accessibility between transmembrane helices
may or may not allow oxidizing agents to reach the site,
although the simulations presented here do indicate that
the neighboring intersubunit cavity has significant water
accessibility. Furthermore, cross-linking experiments have
successfully formed disulfide bridges in the transmembrane
domain (89–92). In classical MD simulations, disulfide
bridges are part of the model and must be specified at the
beginning of the simulation. The simulations reported here
do include disulfide bridges in the a and g subunits.
The impact of disulfide bonds bridging M1 and M3 in the
a and g subunits may be assessed by comparing the localBiophysical Journal 106(9) 1938–1949
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mologous counterparts in b subunits. Across all simulations,
the distance between a carbons of those bridged cysteines
averages 6.4 A˚, with a standard deviation of 0.3 A˚, whereas
the same distance calculated for the homologous pair of res-
idues in the b subunit (S229 and C288) gives an average of
7.0 A˚ and a standard deviation of 0.5 A˚. Thus, the presence
of M1-M3 disulfide cross-links seems to have only a small
effect on the interhelical distance, and cause a slight reduc-
tion in the relative dynamics of these two helices.
The transmembrane domain of the receptor contains mul-
tiple charged residues. Each subunit has an acidic residue
on M3 and a basic residue on M2, on the extracellular
half of the receptor transmembrane domain, as specified in
Methods. These residues form interhelical salt bridges in
the a and g subunits in the model, and the bridges are stable
over the course of the simulations (both with and without
cholesterol). In the b subunit, the analogous residues have
additional salt-bridging partners on the same helices, and
the interhelical salt bridges are not present in the initial co-
ordinates for Model 1 (nor do they form over the simula-
tion). The interhelical salt bridges are present in the initial
coordinates for b subunits in Model 2.Predicted cholesterol binding
One set of starting coordinates for bound cholesterol was
generated by analogy with GluCl-bound ivermectin
(Fig. S3). To confirm in an unbiased manner the possibility
that cholesterol could bind to the intersubunit cavity, auto-
mated docking calculations were performed. The docking
found cholesterol binding modes for each subunit interface
of the GABAAR transmembrane domain, and only in those
sites (after excluding the hydrophobic pore). The docking
process yielded at least one pose with high predicted affin-
ity for each site (typically 7 to 8 kcal/mol). The five
poses are strongly similar, and share major features.
They all occupy the cavity that binds ivermectin in the
template structure, and parts of the cholesterol structureBiophysical Journal 106(9) 1938–1949replace well-defined parts of ivermectin, as illustrated in
Fig. S4.
In agreement with our initial ivermectin-based binding
model, most high-scoring poses place the cyclohexanol
ring of cholesterol in the position of the six-membered ring
of the benzofuran moiety of ivermectin. This places the hy-
droxyl group in position to form a hydrogen bond with the
M2 serine 150, thus mimicking ivermectin interaction with
GluCl (32). At the other end of the steroid core, the cyclopen-
tane ring closely matches one of the six-membered rings in
the spiroketal group of ivermectin. Finally, all five optimally
docked cholesterol molecules share the same orientation,
with the smooth side always facing toward helix M1 of one
subunit and the rough side facing toward helix M3 of the
other (Fig. S4). Considering that this heteromeric a1b1g2
receptor contains five different subunit interfaces, such a
fivefold symmetric docking prediction is remarkable.
The docking poses, however, adopt a different orientation
than predicted by analogy with ivermectin. Although the
aligned coordinates give a mostly horizontal cholesterol
(in the membrane plane), docked cholesterol molecules
are more tilted (Fig. 1). The two families of poses are also
flipped with respect to each other: the rough side of choles-
terol faces M1 in the aligned coordinates, as opposed to M3
in the docked coordinates. Time evolution of these orienta-
tion parameters in MD simulations is described below.Cholesterol-free systems
In the simulations without any directly bound cholesterol,
phospholipid acyl chains initially enter the gaps formed by
the ivermectin binding site; many are expelled from the sites
as they close over the course of the simulations. Although
the model bilayer does contain cholesterol, the relatively
short length of the simulations compared to the likely
timescales required for reorientation and binding of a rigid
molecule like cholesterol preclude the observation of spon-
taneous cholesterol binding to empty intersubunit sites.
However, in simulations starting with bound cholesterol,FIGURE 1 (A) Initial (lines) and final (licorice)
coordinates of bound cholesterol in MD simula-
tions. Blue and black represent Autodock docking
and ivermectin alignment, respectively. Final coor-
dinates for Model 2 are red. (B) Initial and final
coordinates of bound cholesterol in the interface
between the bg (orange) and g (purple) subunits.
Models 1–3 are represented by black, red, and
blue, respectively. Protein side chains lining the
site are shown as spacefill colored by residue
type (white, nonpolar; green, polar; red, acidic;
and blue, basic).
Cholesterol Site on the GABAAR 1943spontaneous unbinding and rebinding events are observed
(as described below).
In both simulated models without directly bound choles-
terol, the pore closes to have a minimum constriction likely
too small to conduct a chloride ion, as discussed further
below (Effect of cholesterol on the ion channel pore). The
minimum constriction is consistently at 90, in contrast to
the minimum constriction in GluCl at20; since 90 is signif-
icantly more hydrophobic, similar to the putative hydropho-
bic gate in the nAChR, it seems likely that a chloride ion
would require a solvation shell to cross this barrier, making
a slight constriction sufficient to block the passage of ions.Dynamics of bound cholesterol
Initial coordinates from both approaches to docking choles-
terol to the GABAAR are shown in Fig. 1. Average distances
(projected onto themembrane plane) of the cholesterol center
of masses from the pore center are shown elsewhere (see
Fig. 5, top) Quantitative data on cholesterol fluctuations are
given in Fig. S5. In general, cholesterol is seen to fluctuate
within the sites, including reorientation and back-and-forth
translation between the opening of the intersubunit cleft and
the M2 helix that separates the cavity from the central pore.
Instances of cholesterol unbinding are observed in
Models 1 and 2. In Model 2, two cholesterol molecules
unbind very rapidly (within 20 ns of simulation time), pre-
sumably due to unfavorable interactions with the pocket.
Perhaps surprisingly, both molecules bind again, 80–110 ns into the simulation, reaching more favorable binding
modes. The process is illustrated in Fig. 2 in the case of the
ab-bg interface. These unexpected events provide examples
of spontaneous binding of cholesterol to the intersubunit
cavities, on a short timescale (<100 ns), although binding
in this case is certainly facilitated by the position of choles-
terol exactly at the opening, in a favorable orientation.
Spontaneous binding of cholesterol from the bulk bilayer
is expected to face an additional entropic barrier.
Cholesterol reorientation is measured by two angle pa-
rameters, flip, which describes rotation around the long
axis, and tilt, which measures the angle formed by the long
axis and the membrane plane. Time trajectories of these pa-
rameters for all simulations are represented in Fig. 3. The flip
coordinate characterizes two main states: if the rough side of
cholesterol faces helix M1, the angle is negative, and if it
faces M3, the angle is positive. Very few flip events are
observed, indicating that these states are separated by high
kinetic barriers, presumably due to the asymmetric shape
of the intersubunit cleft, which disfavors horizontal orienta-
tions of the cholesterol nucleus. One instance of flip (Model
2, ab-bg) sidesteps this barrier by unbinding, flipping while
outside the cavity, then rebinding (Fig. 3). Such a slow flip
motion is reminiscent of the experimental characterization
by electron paramagnetic resonance of nAChR-rich mem-
branes, which found that in such membranes the steroid an-
drostanol experienced hindered rotation around its long axis,
with a rotation time>50 ns (93). Themost likely explanation
for such hindered rotation is tight binding such as thatFIGURE 2 Spontaneous unbinding and rebind-
ing event in an MD simulation. In the inital model
(upper left), cholesterol (orange) is bound between
helices bg M2-M3 (white cartoon) and ab M1 (not
shown). At 17 ns (upper middle), cholesterol has
entirely exited the site and is solvated by the lipid
bilayer (lower, dotted line). At 200 ns (upper
right), it is again deeply bound at the interface,
and forming a hydrogen bond with M2 serine 150
(red arrow). Protein and lipid residues in contact
with cholesterol in each frame are depicted as lic-
orice (yellow, phospholipid; orange, cholesterol;
cyan, abM1; green, bgM2-M3). (Lower) Distance
between cholesterol center of mass and center of
the receptor as a function of time.
Biophysical Journal 106(9) 1938–1949
FIGURE 3 Reorientation of bound cholesterol molecules in five separate MD simulations. Each interface is color-coded (see key). The lines connect suc-
cessive values of the tilt and flip angles for each bound cholesterol molecule. Tilt describes the angle between the cholesterol long axis and the membrane
plane, whereas flip reflects the orientation of an axis orthogonal to the former, in the plane of the sterol nucleus. Simulations of models 1a–1c and 2 start from
(80, 11), whereas initial conditions for model 3 are in the range (50–65,10–35).
1944 He´nin et al.proposed here for the GABAAR and in our previous article
for the nAChR (54).Protein residues interacting with cholesterol
Receptor residues found in frequent contact with bound
cholesterol in all models simulated are listed in Table 1.
Note that the residues are mutually homologous, in accor-
dance with the overall pentameric pseudosymmetry of the
observed binding modes. Based on the ivermectin analogy,
the key residue expected to interact with cholesterol is
serine 150 on helix M2. This interaction is described in detail
in the next section. At each interface, residues belonging to
helices M1 and M3 of the two subunits form a belt of
nonpolar contacts around the steroid nucleus of cholesterolTABLE 1 Residues forming frequent contacts with bound
cholesterol
a1 b1 g2
M1 I228 L223 I238
L232 M227 I242
M236 L231 L246
M2 S270 S265 S280
M3 A291 M286 S301
Y294 F289 F304
Biophysical Journal 106(9) 1938–1949(Fig. 1). These residues are almost exclusively hydrophobic,
with the exception of g2 S301.Hydrogen bonding of cholesterol to M2 serine 150
The role of hydrogen bonding of a pLGIC modulator to a
serine residue on the M2 helix has been discussed in the
case of potentiation of GluCl by ivermectin, based on crys-
tallography (32) and site-directed mutagenesis (94,95).
Examination of a broader range of pLGICs, however, indi-
cates that presence of a serine residue at this location is
not essential for ivermectin sensitivity (96). Most directly
bound cholesterol molecules do form a hydrogen bond
with Ser150, as illustrated in Fig. 2.
In the simulations presented here, serine residues at the
M2 150 position in all a and b subunits are found to form
H-bonds to bound cholesterol for at least 80% of the simu-
lation time for at least one of the models/replicas, with
values for all models/replicas ranging from 0 to 95%, and
with larger variations across models/replicas than across
subunits. A somewhat loose geometric definition designed
to include weak hydrogen bonds was used, as described in
Methods. The cholesterol hydroxyl acts as both donor and
acceptor, with various divisions ranging from pure donor
to pure acceptor across the subunits and simulations. A
A B
C D
E F
Cholesterol Site on the GABAAR 1945sample configuration illustrating such an H-bond is shown
in Fig. S6: the cholesterol headgroup penetrates deep into
the bundle. In the g subunit, however, M2 S150 did not
form an H-bond with cholesterol for >2% of the simulation
time in any of the simulations; we note that the correspond-
ing cholesterol molecules in the b-g interface are those
for which the most convergence across simulations was
observed.
Persistent hydrogen bonds between the cholesterol and
M2 helices could result in a net force contributing to the in-
fluence of cholesterol on pore conformation. A hydrogen
bond under tension would pull the upper part of the M2 he-
lix outward, acting against pore closure. To probe for such
an effect, the force exerted on Ser150 by H-bonded choles-
terol was computed, and its average was found to be a repul-
sion between 50 and 100 pN (0.8–1.5 kcal/mol/A˚) across
simulations and subunits. Thus, hydrogen-bonded choles-
terol does not pull the M2 helix outward but rather, on
average, exerts a force pushing it inward. H-bonding there-
fore does not constitute a direct mechanism that would
explain any reduced pore closure in the presence of bound
cholesterol, yet it stabilizes cholesterol in its bound state.FIGURE 4 Time evolution of the pore radius profile (along the pore axis)
for Models 1 (A–D) and 2 (E and F). Pore radii >3 A˚, between 2 and 3 A˚,
and<2 A˚ are color-coded as light blue, orange, and black, respectively. The
prime numbering corresponds to Leu264 (90), Val257 (20) and Pro253 (20) in
the M2 helix of the a subunit. To see this figure in color, go online.Effect of cholesterol on the ion channel pore
The presence or absence of a ligand in the intersubunit site is
expected to affect the width of the cleft, as was noted by
Yoluk et al. (34) in simulations of GluCl with and without
ivermectin. The authors saw the cleft remain stable in the
presence of ligand and shrink slightly in its absence. A
similar analysis performed on the trajectories in this study
indicates that the cholesterol-bound clefts widen by 1.3 A˚,
whereas cholesterol-free clefts widen by 0.3 A˚ on average.
Fig. 4 shows the time evolution of the pore radius profile
for all systems. The ring of leucines (thought to function as a
hydrophobic gate) occurring at a 264 (M2 90) consistently
forms the most constricted region of the pore. For both
models that were simulated (Models 1 and 2) both with
and without directly bound cholesterol, the addition of
directly bound cholesterol widens the pore in the region
z ¼ 0–15 A˚, which corresponds to the region closest to
the cholesterol hydroxyl. This result is consistent with a
wedge-type mechanism for positive modulation, as pro-
posed for ivermectin activation of GluCl in Hibbs and
Gouaux (32).
The extent to which this widening of the pore near the
cholesterol hydroxyl correlates with widening of the pore at
its narrowest constriction (which would seem to be the
most influential region for determining conduction) is mixed
for the twomodels, however. Fig. 4 indicates that forModel 1,
bound cholesterol clearly widens the narrowest constriction,
as evidenced by a marked reduction in black regions in the
band formed by M2 90 (this effect is consistent across the
three replicas). In Model 2, however, the constriction at M2
90 is largely unchanged in the presence of docked cholesterol.More quantitative analysis can be obtained by defining
multiple average geometric parameters of the M2 helices,
as represented in Fig. 5. The geometric parameters analyzed
are the pore radius, p, at M2 90; the average distance q be-
tween the pore axis and the center of the M2 helix at 90; the
average radial tilt angle, q, of the M2 half-helix on the extra-
cellular side with respect to the pore axis projected along the
radial vector; and the average distance r between the pore
axis and the center of the M2 helix at 150. The latter three pa-
rameters are related, on average, by hqi ¼ hri  l0 sinhqi,
where l0 ¼ 6:4 A˚ is the distance along the helix between
90 and 150. The results from such decomposition indicate
that the presence of cholesterol has similar effects on the
measured distance r in both Models 1 and 2, although the
effect is less pronounced for Model 2. This result is again
consistent with a wedge mechanism, in which cholesterol
widens the radius of the M2 helices at its point of contact.
Furthermore, the difference in distances from the pore axis
to the side chain at 90 and to the helix center at 90 (q  p) is
roughly conserved for all sixModel 1/Model 2 systems, indi-
cating that effects of cholesterol or model dependence of the
pore radius are not determined by rotation of M2 helices or
different conformations of side chains in the pore. The differ-
ence in cholesterol sensitivity of the two models seems to
originate from a higher value of the average tilt angle, q, in
theModel 2 systemwith cholesterol. The origin of this larger
tilt is not clear, but the largest difference in average q betweenBiophysical Journal 106(9) 1938–1949
FIGURE 5 Pore geometric properties, averaged over subunits and simu-
lation frames. Definitions for each property are shown in the insets. Data for
Model 1 (black circles), Model 2 (red triangles), and Model 3 (green
square) are shown. Lines are shown to guide the eye and reflect the implicit
hypothesis that trends should be characterized on a per-model basis. The
first 50 ns of simulation are not included in these averages. To see this figure
in color, go online.
1946 He´nin et al.the two models is found in the b subunits; likewise, the salt
bridge that is present in b subunits for Model 2 and absent
inModel 1 constitutes one of the biggest differences between
the two models. The potential key role of these salt bridges
has been outlined previously (97), although errors in the
then-prevalent Unwin models may have led to inaccurate
placement of some of the residues involved.DISCUSSION
In this work, we investigate the implications of potential
cholesterol binding to intersubunit ivermectin/neurosteroid
sites on the GABAAR. We build models of a human
GABAAR based on the crystal structure of the glutamate-Biophysical Journal 106(9) 1938–1949gated chloride channel of C. elegans. The models bring
to light putative disulfide bridges linking the M1 and M3
transmembrane helices of the a and g subunits. Currently
available evidence is insufficient to confirm or refute the ex-
istence and functional significance of such disulfide bridges;
however, sequence analysis shows that the cysteine residues
involved are characteristic of the a and g subunit types
across all vertebrate GABAARs.
Based on structural and biochemical evidence, we postu-
late a binding mode of cholesterol at the subunit interfaces,
analogous to ivermectin binding to the GluCl receptor. We
construct bound-cholesterol coordinates by alignment with
the ivermectin coordinates of the template. This hypothesis
is confirmed independently by automated docking cal-
culations that show pseudosymmetric binding modes over-
lapping with ivermectin coordinates, although in a slightly
different orientation than we initially postulated. In
explicit-solvent, atomistic MD simulations, we find that
cholesterol is generally stable, but possibly mobile in these
sites, with fluctuations between several orientations. In these
simulations, we observe instances of spontaneous unbinding
and rebinding of cholesterol in poses and orientations
similar to those predicted by docking. On the relatively short
timescale spanned by our simulations, cholesterol tends
to promote pore opening, although that effect is less pro-
nounced in one of the structural models.
Several crystal structures of membrane receptors showing
bound cholesterol molecules have been resolved, starting
with the b2-adrenergic receptor (98); there is also experi-
mental evidence of direct, specific interactions of choles-
terol with membrane channels VDAC (99), KirBac1.1
(100), Kir2 (101), and TRPV1 (102). In general, interactions
documented experimentally occur at the lipid interface and
describe a transmembrane orientation of cholesterol similar
to its bulk bilayer orientation. This model, like our previous
model of interaction with the nAChR, depicts a deeper type
of binding than do most other models, in between TM heli-
ces. Such binding could be very difficult to access experi-
mentally for several reasons, such as slow exchange with
bulk on the timescale of experiments. It could also be rela-
tively unusual and limited to few classes of transmembrane
proteins.
The direct-interaction model presented here lends itself
to experimental testing by mutagenesis. Our bound-choles-
terol structural models indicate key residues that are likely
to be involved in cholesterol interactions and constitute
prime targets for mutagenesis. In addition to M2 Ser150,
already highlighted by biochemical (103) and structural
work (32), residues of helices M1 and M3 are predicted
to form nonpolar contacts with the steroid nucleus of
cholesterol.
Future work will seek to predict the affinity of cholesterol
for these sites; at present, we note that vertebrate GABAARs
reside in cholesterol-rich membranes (36), and that there-
fore it is likely that at least some of these intersubunit sites
Cholesterol Site on the GABAAR 1947are occupied by cholesterol. Binding of neurosteroids or
other modulators may then proceed through exchange be-
tween the cholesterol and the modulator rather than opening
of an empty, collapsed site.SUPPORTING MATERIAL
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